Generex Announces Update on 1:1 Dividend and NASD
Post# of 36537
(Total Views: 400)
Posted On: 02/26/2021 3:22:15 PM
Generex Announces Update on 1:1 Dividend and NASDAQ Listing
MIRAMAR, FL, June 28, 2019, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on the previously announced 1:1 GNBT stock dividend. After discussing our listing with Nasdaq officials and our transfer agent Broadridge Financial Solutions, Inc., the dividend will be paid the day after our listing to the Nasdaq stock exchange, not on the same day as the listing as previously stated. In addition, Generex has been working on the application for the up-listing, and we have notified the Nasdaq that we will be submitting the application in the coming days.
Joe Moscato, President Chief Executive Officer of Generex stated, We are very close to submitting our application to Nasdaq for the up list, and we have gotten p ositive input and direction from Nasdaq officials. The listing on the Nasdaq exchange is the last piece in our
overall plan we put forth in January 2017 and ends with our 1:1 dividend to shareholders after we are listed. We are excited about the potential listing on Nasdaq, which will ensure our future and provide Generex with a significant benefit as it relates to raising capital and investor liquidity while building sustainable value for our shareholders. We will announce to our shareholders when the application is submitted.
All the PR going back to January 2019 https://www.generex.com/investor
MIRAMAR, FL, June 28, 2019, 2019 - Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on the previously announced 1:1 GNBT stock dividend. After discussing our listing with Nasdaq officials and our transfer agent Broadridge Financial Solutions, Inc., the dividend will be paid the day after our listing to the Nasdaq stock exchange, not on the same day as the listing as previously stated. In addition, Generex has been working on the application for the up-listing, and we have notified the Nasdaq that we will be submitting the application in the coming days.
Joe Moscato, President Chief Executive Officer of Generex stated, We are very close to submitting our application to Nasdaq for the up list, and we have gotten p ositive input and direction from Nasdaq officials. The listing on the Nasdaq exchange is the last piece in our
overall plan we put forth in January 2017 and ends with our 1:1 dividend to shareholders after we are listed. We are excited about the potential listing on Nasdaq, which will ensure our future and provide Generex with a significant benefit as it relates to raising capital and investor liquidity while building sustainable value for our shareholders. We will announce to our shareholders when the application is submitted.
All the PR going back to January 2019 https://www.generex.com/investor
(2)
(1)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼